Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for tough stomach cancer

NCT ID NCT05419362

First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 19 times

Summary

This study tested a new combination of two drugs, GEN-001 and avelumab, in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior treatments. Participants had a specific marker (PD-L1 positive) and had not received immunotherapy before. The goal was to see if the combination could shrink tumors and control the disease, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ajou University Hospital

    Gyeonggi-do, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.